Eltrombopag research and development history, market price and purchasing advice

Eltrombopag (Eltrombopag) is a new type of small molecule non-peptide thrombopoietin receptor agonist, widely used in the treatment of chronic immune (idiopathic) thrombocytopenic purpura (ITP), chronic hepatitis C-related thrombocytopenia and severe aplastic anemia. Its research and development history, market price, and purchasing advice are very important to patients and medical professionals.

1. R&D process

The research and development of Eltrombopag began with GlaxoSmithKline in the United Kingdom, and later collaborated with Novartis in Switzerland. After years of clinical research and trials, the drug was approved by the US FDA in November 2008, becoming the world's first and only approved small molecule non-peptide TPO receptor agonist. The advent of Eltrombopag provides a new treatment option for ITP patients, especially those who do not respond well to traditional treatments such as corticosteroids, immunoglobulins, or splenectomy, and fills the treatment gap in this field.

2. Market price

The market price of eltrombopag varies by region, drug version and sales channel. In China, the price of Eltrombopag’s original drug is relatively high, with each box (25mg*28 tablets) selling for about four to five thousand yuan. However, thankfully, this drug has been included in the national medical insurance catalog, and patients can enjoy a certain percentage of medical insurance reimbursement, thus reducing the financial burden.

In comparison, the generic versions of eltrombopag in overseas markets such as India and Laos are more affordable. For example, the price of the Lao Lucius version of 25mg*28 tablets is about five to six hundred yuan, while the price of the Lao Big Bear version is only about six hundred yuan. These generic versions provide patients with more affordable treatment options.

3. Purchase suggestions

1. Choose formal channels: To ensure the quality and safety of the drug, patients should choose formal channels to purchase Eltrombopag. In China, it is recommended to purchase through hospital pharmacies or pharmacies with drug sales qualifications; overseas, you can choose direct mail agencies that cooperate with official pharmacies or go to overseas pharmaceutical factories in person to purchase.

2. Understand the details of the drug: Before purchasing, patients should carefully understand the specifications, origin, production date, expiration date and other information of the drug to ensure that the purchased drug meets their own treatment needs.

3. Pay attention to storage conditions: Eltrombopag should be stored in a dry, cool, and dark place to avoid moisture and high temperature environments. During transportation, medicines also need to be kept dry and protected from light.

4. Follow the doctor's instructions: Eltrombopag is a prescription drug. Patients should consult a doctor before use to understand their indications, usage and dosage, possible adverse reactions, and other information, and strictly follow the doctor's instructions for medication.

5. Pay attention to price dynamics: Since the price of eltrombopag may change due to factors such as region, version, and sales channel, it is recommended that patients pay attention to price dynamics in order to choose drugs with higher cost performance.

To sum up, as an innovative treatment for ITP, eltrombopag's research and development process, market price and purchasing advice are crucial to patients and medical workers. Patients should choose to purchase from formal channels and use it correctly according to doctor's instructions to ensure the safety and effectiveness of the medication.